- Home
- GF vs NBTX Comparison
GF vs NBTX Comparison
Compare GF & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- NBTX
- Stock Information
- Founded
- GF 1990
- NBTX 2003
- Country
- GF Germany
- NBTX France
- Employees
- GF N/A
- NBTX N/A
- Industry
- GF Investment Managers
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- NBTX Health Care
- Exchange
- GF Nasdaq
- NBTX Nasdaq
- Market Cap
- GF 167.2M
- NBTX 178.7M
- IPO Year
- GF N/A
- NBTX 2020
- Fundamental
- Price
- GF $10.07
- NBTX $3.61
- Analyst Decision
- GF
- NBTX Strong Buy
- Analyst Count
- GF 0
- NBTX 1
- Target Price
- GF N/A
- NBTX $12.00
- AVG Volume (30 Days)
- GF 28.1K
- NBTX 13.1K
- Earning Date
- GF 01-01-0001
- NBTX 04-23-2025
- Dividend Yield
- GF 0.82%
- NBTX N/A
- EPS Growth
- GF N/A
- NBTX N/A
- EPS
- GF N/A
- NBTX N/A
- Revenue
- GF N/A
- NBTX $45,220,186.00
- Revenue This Year
- GF N/A
- NBTX N/A
- Revenue Next Year
- GF N/A
- NBTX N/A
- P/E Ratio
- GF N/A
- NBTX N/A
- Revenue Growth
- GF N/A
- NBTX 526.17
- 52 Week Low
- GF $7.38
- NBTX $2.76
- 52 Week High
- GF $9.41
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- GF 57.31
- NBTX 52.08
- Support Level
- GF $10.14
- NBTX $3.32
- Resistance Level
- GF $10.28
- NBTX $3.77
- Average True Range (ATR)
- GF 0.14
- NBTX 0.21
- MACD
- GF -0.07
- NBTX 0.01
- Stochastic Oscillator
- GF 32.56
- NBTX 60.55
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.